- Home
- AGEN vs CGO Comparison
AGEN vs CGO Comparison
Compare AGEN & CGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AGEN | CGO |
|---|---|---|
| Founded | 1994 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 126.2M | 112.9M |
| IPO Year | 2000 | N/A |
Fundamental Metrics
Financial Performance| Metric | AGEN | CGO |
|---|---|---|
| Price | $3.34 | $12.03 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $14.50 | N/A |
| AVG Volume (30 Days) | ★ 983.6K | 34.7K |
| Earning Date | 11-10-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 9.25% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $106,829,000.00 | N/A |
| Revenue This Year | $23.68 | N/A |
| Revenue Next Year | $23.17 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.38 | $7.90 |
| 52 Week High | $7.34 | $10.93 |
Technical Indicators
Market Signals| Indicator | AGEN | CGO |
|---|---|---|
| Relative Strength Index (RSI) | 41.53 | 67.01 |
| Support Level | $3.01 | $11.38 |
| Resistance Level | $4.87 | $12.10 |
| Average True Range (ATR) | 0.36 | 0.12 |
| MACD | 0.05 | 0.05 |
| Stochastic Oscillator | 15.95 | 88.60 |
Price Performance
Historical ComparisonAbout AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
About CGO Calamos Global Total Return Fund
Calamos Global Total Return Fund is a closed-end management investment company. The fund's investment objective is to provide total return through a combination of capital appreciation and current income. The fund invests in equities, convertible securities, and high-yield corporate bonds.